Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.80 |
| ▸ | ACACA | Q13085 | 6/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182592 | 0.89 | ACACB (0.68) | ACACBACACAKDM4EHPGDLMNA | |
| SCHEMBL3462988 | 0.89 | ACACB (1.00) | ACACBACACAKDM4EHPGDLMNA | |
| SCHEMBL3465044 | 0.89 | ACACB (1.00) | ACACBACACAKDM4EHPGDLMNA | |
| SCHEMBL977942 | 0.89 | ACACB (1.00) | ACACBACACAKDM4EHPGDLMNA | |
| SCHEMBL6181355 | 0.86 | ACACB (0.94) | ACACBACACAKDM4EHPGDLMNA | |
| SCHEMBL6184046 | 0.85 | ACACB (0.66) | ACACBACACAKDM4ELMNAALDH1A1 | |
| SCHEMBL6498280 | 0.84 | ACACB (0.91) | ACACBACACAKDM4EHPGDLMNA | |
| SCHEMBL6181251 | 0.83 | ACACB (0.85) | ACACBACACAKDM4ELMNA | |
| SCHEMBL6185409 | 0.83 | ACACB (0.89) | ACACBACACAKDM4ELMNAPOLB | |
| SCHEMBL6184040 | 0.82 | CYP2C9 (0.72) | ACACBACACAKDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979741-B2 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1478437-B1 | ACC INHIBITORS | PFIZER PROD INC (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187254-A1 | Acetyl-CoA carboxylase inhibitors | ACACA, ACACB, ACAT1 | ACACB 2/4885ACACA 1/4885KDM4E 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.